Navigation Links
PARI Pharma's Nebulized DSCG Shows Results Similar to Inhaled Steroids in Asthma Studies Presented at ATS
Date:5/20/2009

chamber.

The study compared various lung function parameters, such as forced expiratory volume in 1 sec (FEV1), forced vital capacity (FVC), mean expiratory flow (MEF 50% pred), inflammatory markers, such as serum percent Eosinophils and expired nitric oxide (FeNo), asthma symptom scores, required beta agonist use, and cortisol levels. The mean asthma symptom score decreased significantly in both treatment groups over the 6 month treatment period from 5.2 +/- 2.5 to 3.07 +/- 2.2 (p=0.021) for the ICS cohort and from 5.6 +/- 1.5 to 3.2 +/- 1.9 (p <0.001) for the IsoCrom group, respectively. No significant change in lung function was observed during the six-month treatment with either inhaled corticosteroids or IsoCrom.

PARI's Comparative in-vitro assessment of IsoCrom & a novel 6% DSCG formulation

Sophisticated aerodynamic droplet and particle size assessments in a cascade impactor operated at different humidity levels revealed how delivery and deposition performance of aerosols can be affected. In-vitro breath simulation tests mimicking breathing patterns of 3 and 10 year old children demonstrated drug delivery performance is nearly unaffected when electronic eFlow Technology nebulizers were used for inhalation. The novel 6% DSCG solution may also offer new therapeutic perspectives due to the combined anti-asthmatic and antiviral potency of DSCG.

"Since the relevance of mast cells in lung vascular remodeling and the development of pulmonary hypertension was also demonstrated in an ATS paper by researchers from Canada, Finland and Germany, nebulized DSCG may also be explored as a new therapeutic for the treatment of pulmonary hypertension," stated Dr. Wolfgang M. Kuebler, professor of vascular physiology and pathophysiology at the Charite University Hospital, Berlin, Germany and associate professor at the Department of Surgery of the University of Toronto, Canada.


'/>"/>

SOURCE PARI Pharma
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ePharmaSolutions Clinical Trial Investigator Portal Wins Bio-IT World 2009 Best Practice Award
2. Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
3. Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients
4. Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)
5. Pharmasset Reports Fiscal Year End 2008 Financial Results
6. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
7. Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications
8. Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th
9. Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
10. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
11. Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... /PRNewswire-iReach/ -- CountryFocus: Healthcare, Regulatory and Reimbursement Landscape ... (Photo - http://photos.prnewswire.com/prnh/20140828/140879 ) ... Landscape Poland " an essential source of information ... market and provides insights into the demographic, regulatory, ... report provides valuable insights into the trends and ...
(Date:8/28/2014)... Aug. 28, 2014 Tianyin Pharmaceutical Co., ... pharmaceutical company that specializes in patented biopharmaceutical, modernized ... pharmaceutical ingredients (API) today updates the timeline for ... (QLF). The Company is scheduled ... for China Food & Drug Administration,s (CFDA) review ...
(Date:8/28/2014)... 2014 /PRNewswire-iReach/ -- Academy Leadership, an elite leadership training ... published a case study highlighting one manager,s ... . In September and October 2014, Academy Leadership affiliates ... Albuquerque , Indianapolis , Salt Lake City ... http://photos.prnewswire.com/prnh/20140828/140814 Leadership training for ...
Breaking Medicine Technology:Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 2Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 3Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 4Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 5TPI Submits Dataset for GMP Inspection at Qionglai Facility (QLF) 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 3Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 4Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 5
... During Wednesday,s Satellite Symposium,3: The Challenges of ... the,International Society of Heart and Lung Transplantation ... researchers discussed some of,the unique challenges in ... CF., A highlight of the session ...
... to be Presented at the Upcoming ECCMID Conference, ... the,press release published on 9 April, Arpida Ltd. ... the clinical programme with,intravenous iclaprim in complicated Skin ... has been presented at last year,s ICAAC,and IDSA ...
Cached Medicine Technology:Lung Transplants in Cystic Fibrosis Patients With Life-Threatening Bacteria Sparks Debate at ISHLT Meeting 2Lung Transplants in Cystic Fibrosis Patients With Life-Threatening Bacteria Sparks Debate at ISHLT Meeting 3Arpida Provides Further Comments on the Pivotal Phase III Trials 2Arpida Provides Further Comments on the Pivotal Phase III Trials 3Arpida Provides Further Comments on the Pivotal Phase III Trials 4
(Date:8/28/2014)... (PRWEB) August 28, 2014 American adults ... industry on the Internet will now have a simpler ... company. In one click this year, some of the ... http://quotespros.com/life-insurance.html . , The promoted plans that ... Pros finder tool represent popular policies. The term, guaranteed ...
(Date:8/28/2014)... NH As the federal government plans its exit strategy ... to rethink its role in providing health care to veterans, ... of Medicine . , "To simply go on doing more ... that the Veterans Health Administration,s cost and population structure pose ... Institute for Health Policy & Clinical Practice, and David Auerbach, ...
(Date:8/28/2014)... and Ann Arbor, MI (PRWEB) August 28, 2014 ... company and the nation’s leading intraoperative neurophysiology monitoring ("IONM") ... and CFO, to the position of Chief Executive Officer ... CFO, was promoted to President and CFO in 2013 ... growth and success. , “Bill’s efforts and achievements ...
(Date:8/28/2014)... Kirklyn Smith, an office manager for EzCOI.com , ... record by walking 5,000 miles in a single year without ... the thousands of individual stories of TrekDesk treadmill desk users ... more than the others. , Kirklyn has launched a website ... a range of 54,823 steps (presumably on an off day) ...
(Date:8/28/2014)... San Mateo, CA (PRWEB) August 28, 2014 ... announce that the MRI Technology program is re-accredited for ... Registry of Magnetic Resonance Imaging Technologists (ARMRIT). , ... re-accreditation. We are constantly improving our program to make ... There is a lot of interest in MRI field ...
Breaking Medicine News(10 mins):Health News:Best Life Insurance Rates for 2014 Now Promoted at Insurer Website 2Health News:A VA exit strategy 2Health News:Biotronic NeuroNetwork Announces the Promotion of Bill Gecsey to CEO 2Health News:There are many reasons why Americans' exercise levels have declined - Meet an executive that refuses to sit still with his TrekDesk Treadmill Desk even in a sedentary job 2Health News:Gurnick Academy’s MRI Program Is Re-Accredited by ARMRIT for the 5 Years 2
... Medical,Equipment, Inc. (Pink Sheets: SHMM) announced today that ... completed its seventh,staffing agreement and is aggressively filling ... CEO of parent company Southern Home Medical,stated, "This ... has far,exceeded their own expectations in their second ...
... June 26, 2008 -- Avalon Pharmaceuticals, Inc. (Nasdaq: AVRX), announced ... candidate in its Beta-catenin Pathway Inhibitor program. This novel compound ... cancer cell death. The Company plans to begin ... is one of the most commonly activated cancer pathways and ...
... Pryor, CEO of Portico,Learning Solutions (Portico), a provider ... Portico,s partnership with FOX,Networks Group (FNG), the umbrella ... Networks, FOX Reality, and the National Geographic,Channel., ... News Corporation businesses,FNG launched a massive effort to ...
... Mandate is Quick to Implement, ROCKLIN, Calif., ... a provider of relay and wireless communications and,professional ... AT&T today announced they would become the,first companies ... a,10-digit numbering system described in the FCC ruling ...
... The International Association for Dental Research (IADR) is presenting ... Lecturer in Periodontology at the School of Dental Sciences ... will be presented at the IADR 86th General Session ... Dr. Preshaw holds a B.D.S. from Newcastle University, a ...
... Va. The International Association for Dental Research ... Diagnostic Sciences (Emeritus) at the School of Dental ... Buffalo, as the 2008,recipient of the Pharmacology/Therapeutics/Toxicology Research ... IADR 86th,General Session & Exhibition in Toronto, ON, ...
Cached Medicine News:Health News:Encore Medical Staffing of Greenville Signs Seventh Staffing Agreement 2Health News:Avalon Pharmaceuticals names lead development candidate in beta-catenin inhibitor program 2Health News:FOX Networks Group in Partnership with Portico Learning Solutions Launches Online Employee Health and Safety Orientation Course for Over 3,300 Employees 2Health News:GoAmerica(R) and AT&T to Demonstrate Fast, Effective 10-Digit Interoperability Between Video Relay Providers 2Health News:GoAmerica(R) and AT&T to Demonstrate Fast, Effective 10-Digit Interoperability Between Video Relay Providers 3Health News:GoAmerica(R) and AT&T to Demonstrate Fast, Effective 10-Digit Interoperability Between Video Relay Providers 4Health News:GoAmerica(R) and AT&T to Demonstrate Fast, Effective 10-Digit Interoperability Between Video Relay Providers 5Health News:Fischman receives Pharmacology/Therapeutics/Toxicology Research Award 2
Kit Nebulizer Small Volume Medication W/Pediatric Mask Mouthpiece 7FT O 2 Tubing...
Nebulizer Adapter Kit 6"...
... Anesthesia and Respiratory Products, ,Westmed designs, ... for Anesthesia and Respiratory professionals. Our mission ... enhance the clinician's ability to deliver quality ... the bottom line. , ,Our web ...
... The Raindrop® medication nebulizer achieves optimum ... MMAD particle size range is 1.04-1.10 µ ... compressor or air outlet., ,As the ... gives healthcare providers the assurance of proven ...
Medicine Products: